Brazil Attention Deficit Hyperactivity Disorder Therapeutic Market Report 2022 to 2030

Brazil ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis

$ 3999

Brazil's Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market is expected to grow from $739 Mn in 2022 to $1,419 Mn in 2030 with a CAGR of 8,5% for the year 2022-30. The rising incidence of ADHD in Brazil and supportive government initiatives by the Brazilian government are responsible for the growth of the market. The Brazil ADHD therapeutics market is segmented by drug, drug type, demographics, and by distribution channel. Some of the key players in the market include Corporacion Bonima, Ovidio J. Vides, and Eli Lily.

ID: IN10BRPH028 CATEGORY: Pharmaceuticals GEOGRAPHY: Brazil AUTHOR: Parul Choudhary

Buy Now

Brazil Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Executive Analysis

The Brazil Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market size is at around $739 Mn in 2022 and is projected to reach $1,419 Mn in 2030, exhibiting a CAGR of 8.5% during the forecast period. Brazil's health spending grew at a 6.3% CAGR from 2019 to 2023, rising by 11% to $33.34 Bn in 2023 from $30.02 Bn in 2022. Brazil's universal health system serves more than 200 Mn people, making it the largest in the world in terms of beneficiaries. However, owing to inadequate public funding, Sistema nico de Sade (SUS) has suffered recently. Currently, Brazil invests about 4% of its GDP on health, compared to the OECD average of about 9.5%. The 6% level is advised by the Pan American Health Organization (PAHO).

Around the globe, 5.3% of children and adolescents suffer from attention-deficit/hyperactivity disorder (ADHD), a common psychiatric disorder. The prevalence rate of ADHD in Brazil was reported from 1.5% to 18% according to seven different studies. Although there is no known cure for ADHD, some treatments can undoubtedly lessen symptoms and help people live healthier lives. Major ADHD treatments are recommended based on symptoms and include psychotherapy, medication, specialized training, or a combination of all of these in Brazil. The use of this disorder's medicine has significantly reduced impulsive behavior and hyperactivity over time. Medication for ADHD treatment can gradually help the condition improve with improved focus, attention to work, and learning capacity. In Brazil, stimulants such as methylphenidate (Ritalin) and dextroamphetamine (Dexedrine) are the most frequently prescribed medicines for the treatment of ADHD. Brazilian legislation strictly controls the use of these drugs and only allows access to them with a doctor's prescription. In Brazil, behavioral treatment for ADHD frequently entails collaboration with a psychologist or therapist to create coping mechanisms for symptoms like impulsivity, hyperactivity, and inattention. Techniques like cognitive-behavioral treatment, social skills instruction, and parent training may fall under this category.

brazil attention deficit hyperactivity disorder therapeutics market analysis

Market Dynamics

Market Growth Drivers

The advancement of new technologies that may assist patients in managing their symptoms and enhancing treatment outcomes is possible given the growing accessibility of digital tools and mobile health applications. This may result in more money being spent on research and development in Brazil ADHD therapeutics market. In recent years, the Brazilian government has implemented various public health initiatives and expanded the Unified Health System (SUS) in an effort to increase access to healthcare. These programs should make it easier for Brazilian patients with ADHD to access treatment.

Market Restraints

Many Brazilians still have trouble getting healthcare services, especially those who live in rural or remote areas, despite the government's efforts to increase access. This may restrict the ability to diagnose and manage ADHD, which may in turn restrict the expansion of the Brazil ADHD therapeutics market. Many Brazilians, especially those without health insurance, may find the expense of ADHD medication and treatment to be prohibitive. In particular, for those who are most in need, this may restrict the market for ADHD therapeutics and treatment choices.

Competitive Landscape

Key Players

Guardado (BRA)
Laboratorios Arsal (BRA)
Grupo Paill (BRA)
Corporacion Bonima (BRA)
Ovidio J. Vides (BRA)
Eli Lily
Pfizer
Lupin
Mallinckrodt
Purdue Pharma

Healthcare Policies and Regulatory Landscape

The Brazilian Food and Drug Administration is governed by the Brazilian Health Surveillance Agency, also known as ANVISA, which is short for "Agencia Nacional de Vigilancia Sanitaria" in Portuguese. The organization is associated with the Ministry of Health within the federal public regulatory framework. ANVISA's main objective is to safeguard and advance public health by conducting health monitoring on goods and services, including procedures, components, and technological advancements that could be harmful to consumers' health. The licensing of pharmaceutical labs and other businesses involved in the pharmaceutical production process is the responsibility of ANVISA. Furthermore, the organization is in charge of creating rules that apply to clinical trials (in terms of drug Chemistry, Manufacturing, and Control (CMC) and subject safety). ANVISA collaborates with the Chamber of medication Market Regulation (CMED) to control medication pricing, along with the Health Ministry and other ministries that are members of the organization.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Segmentation

By Drug Type (Revenue, USD Billion):

Stimulants
- Amphetamine
- Methylphenidate
- Dextroamphetamine
- Dexmethylphenidate
- Lisdexamfetamine
- Others
Non-Stimulants
- Atomoxetine
- Bupropion
- Guanfacine
- Clonidine

By Age Group (Revenue, USD Billion):

Pediatric And Adolescent
Adult

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Speciality Clinics
Retail Pharmacies
e-Commerce

By Psychotherapy (Revenue, USD Billion):

Behaviour Therapy
Cognitive Behavioral Therapy
Interpersonal Psychotherapy
Family Therapy

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.